Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial.
Sulkowski
Mark S
MS
Dieterich
Douglas T
DT
Bini
Edmund J
EJ
Bräu
Norbert
N
Alvarez
Daniel
D
Dejesus
Edwin
E
Leitz
Gerhard J
GJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy*; D000998:Antiviral Agents / Q000009:adverse effects*; D004334:Drug Administration Schedule; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000150:complications; D006397:Hematinics / Q000627:therapeutic use*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects*
D000998:Antiviral Agents; D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D012254:Ribavirin; D000068817:Epoetin Alfa; D007372:Interferons